Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedJul 10, 2026
DataAggregated Company Financials
Companies319
  • 7D-0.5%
  • 3M13.6%
  • 1Y45.8%
  • YTD14.3%

Over the last 7 days, the Pharma industry has remained flat, although notably Crinetics Pharmaceuticals gained 98%. As for the the longer term, the industry is up 46% over the past 12 months. Earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 10 Jul 2026US$2.6tUS$425.2bUS$66.0b15.3x39.3x6.1x
Sun, 07 Jun 2026US$2.4tUS$424.1bUS$66.3b14.9x36.4x5.7x
Tue, 05 May 2026US$2.3tUS$416.3bUS$62.4b16.9x36.1x5.4x
Thu, 02 Apr 2026US$2.3tUS$405.9bUS$71.7b16.8x31.7x5.6x
Sat, 28 Feb 2026US$2.4tUS$405.9bUS$72.4b20.1x32.7x5.8x
Mon, 26 Jan 2026US$2.3tUS$404.7bUS$73.2b19.8x31.4x5.7x
Wed, 24 Dec 2025US$2.3tUS$402.8bUS$71.4b19.7x31.6x5.6x
Fri, 21 Nov 2025US$2.1tUS$402.7bUS$71.4b19.4x30.1x5.3x
Sun, 19 Oct 2025US$1.9tUS$389.2bUS$63.5b17.6x29.4x4.8x
Tue, 16 Sep 2025US$1.8tUS$387.9bUS$60.9b18.8x29.3x4.6x
Thu, 14 Aug 2025US$1.7tUS$387.8bUS$60.6b19.8x27.3x4.3x
Sat, 12 Jul 2025US$1.8tUS$382.7bUS$61.3b18.2x28.8x4.6x
Mon, 09 Jun 2025US$1.7tUS$382.7bUS$61.2b17.1x28.1x4.5x
Wed, 07 May 2025US$1.8tUS$382.9bUS$63.7b16.8x27.7x4.6x
Fri, 04 Apr 2025US$1.8tUS$379.9bUS$41.3b15.7x43.5x4.7x
Sun, 02 Mar 2025US$2.0tUS$381.1bUS$39.3b16.7x49.8x5.1x
Tue, 28 Jan 2025US$1.8tUS$370.4bUS$30.5b19x59.2x4.9x
Thu, 26 Dec 2024US$1.8tUS$369.4bUS$31.1b17.3x58.4x4.9x
Sat, 23 Nov 2024US$1.8tUS$373.8bUS$30.6b20.5x59.2x4.8x
Mon, 21 Oct 2024US$2.0tUS$365.3bUS$23.7b18.6x85.8x5.6x
Wed, 18 Sep 2024US$2.1tUS$364.3bUS$25.3b19x81x5.6x
Fri, 16 Aug 2024US$2.0tUS$362.0bUS$21.9b17.3x91.7x5.5x
Sun, 14 Jul 2024US$2.0tUS$357.7bUS$13.8b15.9x146.2x5.7x
Tue, 11 Jun 2024US$1.9tUS$358.3bUS$14.1b19x138x5.4x
Thu, 09 May 2024US$1.9tUS$358.2bUS$13.9b21x133.4x5.2x
Sat, 06 Apr 2024US$1.9tUS$355.2bUS$22.7b24.7x82x5.2x
Mon, 04 Mar 2024US$1.9tUS$355.3bUS$22.5b24.1x85x5.4x
Wed, 31 Jan 2024US$1.8tUS$351.7bUS$24.9b28.7x71.3x5.1x
Fri, 29 Dec 2023US$1.7tUS$375.2bUS$33.8b32.1x49.8x4.5x
Sun, 26 Nov 2023US$1.7tUS$375.1bUS$33.9b26.2x48.8x4.4x
Tue, 24 Oct 2023US$1.6tUS$382.7bUS$44.7b14.7x36.7x4.3x
Thu, 21 Sep 2023US$1.7tUS$381.8bUS$43.9b18.3x39.1x4.5x
Sat, 19 Aug 2023US$1.8tUS$381.6bUS$44.1b18.5x40.3x4.6x
Mon, 17 Jul 2023US$1.7tUS$392.8bUS$60.2b18.3x27.7x4.2x
Price to Earnings Ratio

27.7x


Total Market Cap: US$1.7tTotal Earnings: US$60.2bTotal Revenue: US$392.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 54.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 39.3x which is lower than its 3-year average PE of 54.3x.
  • The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 3.1% per year over the last three years.
  • Revenues for these companies have grown 2.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.59%
Healthcare-0.37%
Pharma-0.48%
Pharma-0.48%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CRNX Crinetics PharmaceuticalsUS$83.6298.0%
+US$4.4b		161.4%PS488x
LLY Eli LillyUS$1.22k0.3%
+US$2.7b		53.9%PE42.9x
EWTX Edgewise TherapeuticsUS$48.3522.2%
+US$945.7m		248.6%PB10.5x
DFTX Definium TherapeuticsUS$48.459.6%
+US$565.5m		498.1%PB23.1x
ALMS AlumisUS$30.3014.3%
+US$484.5m		751.1%PS459.8x

Latest News

MRK
US$125.07
Merck
7D
-3.5%
1Y
48.9%
TEVA
US$33.10
Teva Pharmaceutical Industries
7D
-4.4%
1Y
100.2%
JNJ
US$259.10
Johnson & Johnson
7D
-1.5%
1Y
64.3%
ELAN
US$24.62
Elanco Animal Health
7D
-1.5%
1Y
63.7%
BLTE
US$153.24
Belite Bio
7D
4.5%
1Y
147.0%
CORT
US$93.25
Corcept Therapeutics
7D
3.4%
1Y
29.5%
DFTX
US$48.45
Definium Therapeutics
7D
9.6%
1Y
498.1%
MBX
US$65.71
MBX Biosciences
7D
13.7%
1Y
429.9%
CRNX
US$83.62
Crinetics Pharmaceuticals
7D
98.0%
1Y
161.4%
EWTX
US$48.35
Edgewise Therapeutics
7D
22.2%
1Y
248.6%
ALMS
US$30.30
Alumis
7D
14.3%
1Y
751.1%
BMY
US$57.94
Bristol-Myers Squibb
7D
-0.3%
1Y
19.4%
Seeking Alpha • Jul 03

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

Summary BMY’s growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1’26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow. I reiterate my Buy rating for patient, income-oriented investors, with the recommendation to accumulate at yields above 4.2% for an inflation beating income thesis. Read the full article on Seeking Alpha
VTRS
US$16.34
Viatris
7D
-2.2%
1Y
76.6%
LLY
US$1,216.95
Eli Lilly
7D
0.3%
1Y
53.9%
PFE
US$24.25
Pfizer
7D
-0.3%
1Y
-5.9%
MANE
US$124.91
Veradermics
7D
-3.7%
1Y
n/a